2014
Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. Journal Of Clinical Oncology 2014, 32: 3744-3752. PMID: 25332249, PMCID: PMC4226805, DOI: 10.1200/jco.2014.55.5730.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptorOverall survivalBreast cancerEpidermal growth factor receptorGrowth factor receptorNCCTG N9831NSABP BEarly-Stage Human Epidermal Growth Factor ReceptorHER2-positive operable breast cancerNational Surgical Adjuvant BreastLarge adjuvant trialsOperable breast cancerAddition of trastuzumabAnti-HER2 agentsFactor receptorSurvival end pointsBreast cancer resultsDFS ratesOverall DFSAdjuvant BreastAdjuvant chemotherapyAdjuvant trialsOS ratesMedian timePatient subgroups
2011
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer
Olson EM, Lin NU, DiPiro PJ, Najita JS, Krop IE, Winer EP, Burstein HJ. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Annals Of Oncology 2011, 23: 93-97. PMID: 21531783, PMCID: PMC3276325, DOI: 10.1093/annonc/mdr061.Peer-Reviewed Original ResearchConceptsAnti-HER2 therapyMetastatic breast cancerHER2-positive MBC patientsT-DM1MBC patientsBreast cancerHER2-positive metastatic breast cancerSingle-agent T-DM1Positive metastatic breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Blinded radiology reviewAnti-HER2 agentsGrowth factor receptor 2Kaplan-Meier estimatesFurther clinical benefitFactor receptor 2Protocol therapyMedian durationFurther therapyPartial responseRadiology reviewClinical benefitSubsequent linesMetastatic therapy
2009
Dose-Dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as Biomarkers of Cardiotoxicity.
Morris P, Chen C, Lin N, Moy B, Come S, Abbruzzi A, Patil S, Winer E, Norton L, Hudis C, Dang C. Dose-Dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel (P) with Trastuzumab (T) and Lapatinib (L) in Early Breast Cancer (EBC); Troponin I and C-Reactive Protein as Biomarkers of Cardiotoxicity. Cancer Research 2009, 69: 3088-3088. DOI: 10.1158/0008-5472.sabcs-09-3088.Peer-Reviewed Original ResearchLeft ventricular ejection fractionCongestive heart failureC-reactive proteinEarly breast cancerBiomarkers of cardiotoxicityMinimal elevationEvidence of CHFElevated C-reactive proteinTroponin IDose-dense doxorubicinSensitive inflammatory markerAnti-HER2 agentsVentricular ejection fractionPre-planned analysisCardiac troponin IElevated TnIUncontrolled arrhythmiaWeekly paclitaxelInflammatory markersMUGA scanUnstable anginaEjection fractionHeart failureRecent MIProspective study